Click a keyword to view all the abstracts on this site tagged with that keyword.
- microglia
- Microparticles
- microparticles and coagulation disorder
- microparticles and mitochondria
- microparticles and monocytes
- microparticles and neutrophils
- microparticles and pharmacotherapy
- microparticles and platelets
- microparticles and rheumatoid arthritis (RA)
- microparticles and serologic tests
- Microparticles and systemic lupus erythematosus (SLE)
- microparticles and systemic sclerosis
- microparticles and thrombosis
- MicroRNA
- MicroRNA and ankylosing spondylitis (AS)
- MicroRNA and anti-TNF therapy
- MicroRNA and atherosclerosis
- MicroRNA and biomarkers
- MicroRNA and cytokines
- MicroRNA and dermatomyositis
- MicroRNA and familial Mediterranean fever
- MicroRNA and fibroblasts
- MicroRNA and glucocorticoids
- MicroRNA and innate immunity
- MicroRNA and interferons
- MicroRNA and lupus nephritis
- MicroRNA and psoriatic arthritis
- MicroRNA and remission
- MicroRNA and rheumatoid arthritis
- MicroRNA and rheumatoid arthritis (RA)
- MicroRNA and salivary gland
- MicroRNA and scleroderma
- MicroRNA and Sjӧgrens
- MicroRNA and Sjogren's syndrome
- MicroRNA and SLE
- MicroRNA and systemic lupus erythematosus (SLE)
- MicroRNA and systemic sclerosis
- MicroRNA and vasculitis
- Microscopic Polyangiitis
- microsimulation and quality-adjusted life years
- Microvascular dysfunction
- microvasculature
- Midkine
- Migration inhibitory factor (MIF)
- milestone
- milestones
- military and deployment
- Milnacipran
- Mimickers
- mindfulness
- mindfulness and Chronic pain
- mineralization
- Minority Health
- mir
- miR-146a-5p
- miR15a/16-1
- miRNA
- MIS-C
- Miscellaneous
- miscellaneous and rheumatic disease
- Miscellaneous Rheumatic and Inflammatory Diseases
- Missing data
- missing data and multiple imputation
- Mitochondria
- mitochondria and inflammasome activation
- mitochondria and monocytes
- mitochondria and myositis
- mitochondria and nephritis
- mitochondria and osteoarthritis
- mitochondria and rheumatoid arthritis (RA)
- mitochondria and risk
- mitochondria and synovium
- mitochondria and systemic lupus erythematosus (SLE)
- mitochondria and uric acid
- Mitochondrial Dysfunction
- mitogen-activated protein kinase-activated protein kinase-2
- Mixed Connective Tissue Disease
- Mixed connective tissue disease (MCTD)
- Mixed connective tissue disease (MCTD) and outcomes
- Mixed connective tissue disease (MCTD) and pulmonary fibrosis
- mixed connective tissue disease (MCTD) and ribonucleoprotein (RNP)
- Mixed connective tissue disease (MCTD) and rituximab
- mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE)
- mixed connective tissue disease (MCTD) and systemic sclerosis
- MKL1 and BONE EROSION
- MMF
- MMP and VDIPEN
- mobile health apps
- Model Business
- modifiable risk
- modifiable risk and African-Americans
- modifiable risk and environmental factors
- modifiable risk and obesity
- modifiable risk and osteoarthritis
- modifiable risk and prevention
- modifiable risk and rheumatoid arthritis (RA)
- modified stoke ankylosing spondylitis spinal score (MSASSS)
- modified stoke ankylosing spondylitis spinal score (MSASSS) and bone density
- modified stoke ankylosing spondylitis spinal score (MSASSS) and psoriatic arthritis
- modified stoke ankylosing spondylitis spinal score (MSASSS) and radiography
- modified stoke ankylosing spondylitis spinal score (MSASSS) and risk assessment
- modified stoke ankylosing spondylitis spinal score (MSASSS) and syndesmophyte
- modified stoke ankylosing spondylitis spinal score (MSASSS) and x-ray
- molecular mimicry
- molecular signature
- monitoring
- monoclonal antibodies
- monoclonal antibodies and cancer treatments
- monoclonal antibodies and clinical trials
- monoclonal antibodies and infection
- monoclonal antibodies and neutrophils
- monoclonal antibodies and osteoarthritis
- monoclonal antibodies and pharmacokinetics
- monoclonal antibodies and psoriatic arthritis
- monoclonal antibodies and randomized trials
- monoclonal antibodies and rheumatoid arthritis
- monoclonal antibodies and rheumatoid arthritis (RA)
- monoclonal antibodies and rituximab
- monoclonal antibodies and safety
- monoclonal antibodies and scleroderma
- monoclonal antibodies and spondylarthritis
- monoclonal antibodies and systemic lupus erythematosus (SLE)
- monoclonal antibodies and technology
- monoclonal antibodies and vasculitis
- Monoclonal Gammopathy
- monocytes
- monocytes and ANCA
- monocytes and myositis
- monocytes and neutrophils
- monocytes and osteoarthritis
- monocytes and osteoclastogenesis
- monocytes and osteoclasts
- monocytes and pathogenesis
- monocytes and platelets
- monocytes and polymyalgia rheumatica
- monocytes and proteomics
- monocytes and regulatory cells
- monocytes and rheumatic disease
- monocytes and rheumatoid arthritis
- monocytes and rheumatoid arthritis (RA)
- monocytes and scleroderma
- monocytes and signal transduction
- monocytes and spondylarthritis
- monocytes and synovial cells
- monocytes and synovitis
- monocytes and synovium
- monocytes and systemic lupus erythematosus (SLE)
- monocytes and systemic sclerosis
- monocytes and T cells
- monocytes and thrombosis
- monocytes and toll-like receptors
- monocytes and transcriptional regulation
- monocytes and transforming growth factor
- monocytes and tumor necrosis factor (TNF)
- monocytes and uric acid
- Monocytes/macrophages
- monogenic diseases and asthma
- mononeuritis multiplex
- Monosodium urate crystals
- monotherapy and Biologic agents
- Monozygotic twins
- month of birth
- mood
- morbidity
- morbidity and mortality
- morbidity and mortality and ANCA
- morbidity and mortality and Hispanic patients
- morbidity and mortality and lung transplant
- morbidity and mortality and myositis
- morbidity and mortality and nephritis
- morbidity and mortality and opportunistic infections
- morbidity and mortality and osteoarthritis
- morbidity and mortality and osteoporosis
- morbidity and mortality and outcomes
- morbidity and mortality and parathyroid hormone
- morbidity and mortality and patient-reported outcome measures
- Morbidity and mortality and polymyalgia rheumatica
- Morbidity and mortality and polymyositis/dermatomyositis (PM/DM)
- morbidity and mortality and population studies
- Morbidity and mortality and psoriatic arthritis
- morbidity and mortality and race/ethnicity
- morbidity and mortality and renal disease
- morbidity and mortality and rheumatic disease
- morbidity and mortality and rheumatoid arthritis (RA)
- morbidity and mortality and risk assessment
- morbidity and mortality and rituximab
- Morbidity and mortality and sarcoidosis
- morbidity and mortality and scleroderma
- morbidity and mortality and sex bias
- morbidity and mortality and spondylarthritis
- morbidity and mortality and statins
- morbidity and mortality and synthetase syndrome
- Morbidity and mortality and systemic lupus erythematosus (SLE)
- Morbidity and mortality and systemic sclerosis
- morbidity and mortality and takayasu arteritis
- morbidity and mortality and thrombosis
- morbidity and mortality and tophaceous gout
- morbidity and mortality and treatment
- Morbidity and mortality and uric acid
- morbidity and mortality and vasculitis